Condition
T Cell Lymphoma in Relapse
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Cd4 Car T Cells
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1 (1)
Trial Status
Unknown1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Cd4 Car T Cells1
Active Sponsors
- iCAR Bio Therapeutics Ltd.1
- iCell Gene Therapeutics1
- Peking University Shenzhen Hospital1
Top Investigators
Chengdu Military Hospital
Peking University Shenzhen Hospital, China
Related Conditions
- Refractory Tcell Lymphoma1